AVIEW LCS vs Imbio PHA (4.0.0)
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your institution requires a comprehensive AI solution for lung cancer screening that extends beyond nodule detection to include integrated assessments for COPD and coronary artery calcification from a single low-dose CT scan. This tool is ideal for programs needing automated nodule comparison in follow-up scans and detailed multi-organ risk stratification.
View AVIEW LCS →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your primary need is rapid, automated analysis of cardiac structures from CT pulmonary angiogram (CTPA) scans to assist in the diagnosis and risk stratification of pulmonary embolism or hypertension. This solution is best suited for workflows focused on quickly assessing right ventricular dilation and related ratios to inform acute clinical decisions.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | Imbio PHA (4.0.0) |
|---|---|---|
| Pricing | Contact for pricing | Unknown |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSAVIEW LCS emphasizes streamlining radiology workflows from detection to follow-up and offers comprehensive, automated report generation, including patient-facing detailed analysis reports. Its explicit claim of saving up to 60% of reading time suggests a significant positive impact on user efficiency. While Imbio PHA also offers rapid, automated assessment and seamless PACS integration, AVIEW LCS provides a broader range of workflow enhancements.
Clinical Value
AVIEW LCSAVIEW LCS offers a comprehensive 'Big 3' assessment for lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, enhancing diagnostic accuracy across multiple prevalent conditions. Studies indicate its ability to reduce the likelihood of misidentifying lung nodules compared to human radiologists and significantly reduce workload. Imbio PHA, while valuable for PE/HTN risk stratification, has a more specialized focus.
Pricing & Value
TieBoth tools require direct contact with the vendor for specific pricing information, making a definitive comparison of their cost impossible. While AVIEW LCS does provide insight into its pricing model (one-off or subscription based on installations/users), neither offers transparent pricing to assess direct value for money.
Enterprise Readiness
AVIEW LCSBoth tools are FDA-cleared, HIPAA compliant, and offer flexible deployment options, including cloud and on-premise solutions. However, AVIEW LCS explicitly lists a broader range of deployment options, including 'Hybrid solution' and 'Locally virtualized (virtual machine, Docker)', which may offer greater adaptability for diverse and complex enterprise IT environments. AVIEW LCS also highlights its seamless fit into radiology infrastructure and worklist integration.
Innovation
AVIEW LCSAVIEW LCS demonstrates broader innovation by providing an integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, utilizing CT kernel conversion AI technology. This multi-disease screening approach from a single scan, coupled with automated nodule comparison for follow-up, represents a more expansive application of AI in diagnostic imaging. Imbio PHA's innovation is focused on a specific, albeit valuable, diagnostic aid for PE/HTN.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA provides readily accessible user manuals online and a dedicated support email address for inquiries and malfunction reports. While AVIEW LCS mentions 'Local Technical & Clinical Support' through partners, Imbio's explicit and direct provision of comprehensive support documentation and contact information offers greater transparency and ease of access for users.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | Imbio PHA (4.0.0) |
|---|---|---|
| Name | AVIEW LCS | Imbio PHA (4.0.0) |
| Company | Coreline Soft Co. | Imbio |
| Tagline | AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment | Transforming Imaging with AI to turn medical images into life-changing insights. |
| Categories | Cardiology AI, Oncology AI, Radiology & Imaging AI | Cardiology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Oncology, Pulmonology, Radiology | Cardiology, Pulmonology, Radiology |
| Key Features (Lung Nodule Detection/Analysis) | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Automated comparison of nodules in follow-up CT scans | Not specified |
| Key Features (Cardiac Assessment) | Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass) | Automated measurement of right and left ventricle diameters, Automated measurement of main pulmonary artery and aorta diameters, Calculates RV/LV and PA/Ao ratios |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and Imbio PHA (4.0.0).